Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


More On

Takeda faces multiple suits over diabetes drug Actos

Drug suspected to cause bladder cancer

Japan-based Takeda Pharmaceuticals has been hit with an onslaught of lawsuits over its diabetes drug Actos. Many patients who took the drug to treat their diabetes claim it caused bladder cancer. Takeda halted sales of Actos in June.

Both the Food & Drug Administration and the European Medicines Agency have issued warnings regarding the drug but have not pulled it from the market.

Read more about the concerns over Actos


Cathleen Flahardy

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.